
The USFDA has classified the manufacturing facility of Biocon Sdn Bhd, a group firm of Biocon Ltd at Johor, Malaysia, as 'official action indicated' following a recent inspection. This status, as mentioned by the company in a regulatory filing, may result in delays or withholding of pending product approvals or supplements from the facility. The inspection classification implies that the USFDA might hold back the approval of any pending product applications until the observed non-compliance issues related to manufacturing norms are addressed. In response, Biocon has submitted a comprehensive Corrective and Preventive Action (CAPA) plan and is committed to resolving the concerns. The company aims to work closely with the agency to address any outstanding issues promptly. Despite the development, Biocon remains confident that the incident will not significantly impact the manufacturing and distribution of its commercial products in the US market.
Like
Save
Share